多靶点MLC追踪在前列腺癌VMAT中的首次实验评估
本研究在标准直线加速器上集成实时多靶点MLC追踪与三维X线影像引导,对局部晚期前列腺癌的静态淋巴结模体和动态前列腺模体实施VMAT治疗。结果显示多靶点追踪较单靶点追踪和无追踪降低了剂量学与几何误差,系统延迟为730±20 ms。
要点
- 多靶点MLC追踪可同时独立追踪前列腺和淋巴结位移。
- 多靶点追踪较单靶点和无追踪降低剂量学与几何误差。
- 系统延迟为730±20 ms。
核心结论
- 首次实验实现多靶点追踪在VMAT中独立追踪前列腺和淋巴结位移。
- 多靶点追踪较单靶点追踪和无追踪降低了剂量学与几何误差。
研究设计与样本
- 在标准直线加速器上集成实时多靶点MLC追踪与三维X线影像引导。
- 将三例局部晚期前列腺癌治疗计划递送至静态淋巴结模体和重现三种前列腺轨迹的动态前列腺模体。
- 分别采用多靶点MLC追踪、单靶点MLC追踪和无追踪递送治疗,用Gafchromic胶片测量剂量。
主要发现
- 前列腺和淋巴结的平均(范围)gamma失败率在多靶点追踪下分别为18.6%(5.2%,28.5%)和7.5%(1.1%,13.7%)。
- 单靶点追踪下前列腺和淋巴结的平均(范围)gamma失败率分别为7.9%(0.7%,15.4%)和37.8%(18.0%,57.9%)。
- 无追踪下前列腺和淋巴结的平均(范围)gamma失败率分别为38.1%(0.6%,75.3%)和37.2%(29%,45.3%)。
- 多靶点追踪的几何误差最低,前列腺为0.2±1.5 mm,淋巴结为0.0±0.3 mm。
- 系统延迟为730±20 ms。
关键数值与推荐
- 剂量学误差以2%/2 mm gamma失败率量化。
- 几何误差以靶区与孔径位置之间的错位评估。
临床怎么用
- 多靶点MLC追踪可在VMAT中同时追踪前列腺和淋巴结,降低剂量学和几何误差。
- 系统延迟为730±20 ms,临床部署需考虑该延迟对追踪精度的影响。
局限性
- 研究为模体实验,非临床患者治疗。
- 仅纳入三例局部晚期前列腺癌治疗计划和三种前列腺轨迹。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Locally advanced and oligometastatic cancer patients require radiotherapy treatment to multiple independently moving targets. There is no existing commercial solution that can simultaneously track and treat multiple targets. This study experimentally implemented and evaluated a real-time multi-target tracking system for locally advanced prostate cancer. METHODS: Real-time multi-target MLC tracking was integrated with 3D x-ray image guidance on a standard linac. Three locally advanced prostate cancer treatment plans were delivered to a static lymph node phantom and dynamic prostate phantom that reproduced three prostate trajectories. Treatments were delivered using multi-target MLC tracking, single-target MLC tracking, and no tracking. Doses were measured using Gafchromic film placed in the dynamic and static phantoms. Dosimetric error was quantified by the 2%/2 mm gamma failure rate. Geometric error was evaluated as the misalignment between target and aperture positions. The multi-target tracking system latency was measured. RESULTS: The mean (range) gamma failure rates for the prostate and lymph nodes, were 18.6% (5.2%, 28.5%) and 7.5% (1.1%, 13.7%) with multi-target tracking, 7.9% (0.7%, 15.4%) and 37.8% (18.0%, 57.9%) with single-target tracking, and 38.1% (0.6%, 75.3%) and 37.2% (29%, 45.3%) without tracking. Multi-target tracking had the lowest geometric error with means and standard deviations within 0.2 ± 1.5 for the prostate and 0.0 ± 0.3 mm for the lymph nodes. The latency was 730 ± 20 ms. CONCLUSION: This study presented the first experimental implementation of multi-target tracking to independently track prostate and lymph node displacement during VMAT. Multi-target tracking reduced dosimetric and geometric errors compared to single-target tracking and no tracking.
引用
- Hewson EA, Dipuglia A, Kipritidis J, et al. First experimental evaluation of multi-target multileaf collimator tracking during volumetric modulated arc therapy for locally advanced prostate cancer. Radiother Oncol. 2021. PMID: 33971194. doi:10.1016/j.radonc.2021.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。